16-hydroxycleroda-3,13-dien-15,16-olide and N-methyl-actinodaphine potentiate tamoxifen-induced cell death in breast cancer

8Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

In this study, we investigated whether 16-hydroxycleroda-3,13-dien-15,16-olide (HCD) and N-methyl-actinodaphine (MA) could sensitize breast cancer cells to Tamoxifen (TMX) treatment. MA or HCD alone or in combination with TMX dose-dependently inhibited MCF-7 and MDA-MB-231 cell growth, with a more potent inhibition on MDA-MB 231 cells. Furthermore, this novel combination significantly induced S and G2/M cell cycle phase in MDA-MB 231 than MCF-7 cells. Further determination of the apoptotic induction showed that MA or HCD and TMX combination inhibited MDA-MB-231 and MCF-7 cancer cells by upregulating Bax and by downregulating Bcl-2 mRNA and protein expression without altering Caspase-8 and Caspase-12 expression. These results suggest that MA or HCD pretreatment may potentiate the anti-tumor effect of tamoxifen on breast cancer.

Author supplied keywords

Cite

CITATION STYLE

APA

Velmurugan, B. K., Wang, P. C., & Weng, C. F. (2018). 16-hydroxycleroda-3,13-dien-15,16-olide and N-methyl-actinodaphine potentiate tamoxifen-induced cell death in breast cancer. Molecules, 23(8). https://doi.org/10.3390/molecules23081966

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free